Replies to post #122484 on Biotech Values

[mcbio]

For the record, HALO has been talking deal for several years. BIOD even before they went public.

As it relates to BIOD, is it possible that a big part of their reason for not finding a partner for Linjeta before may have been due to the tolerability issues with that drug? BIOD is hoping to overcome the tolerability issues in the two new versions, and early results appear promising (#msg-65890035 ). And now, BIOD seems to be working on a potentially improved insulin analog as well.